Quando iniciar o tratamento com secukinumabe em pacientes com espondiloartropatia axial: antes ou depois do tratamento com anti-TNFα?
Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007
Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.
Ak et al. sought to determine the optimal time to start secukinumab treatment. The study demonstrated a significant difference between baseline and post treatment BASDAI scores, across both the TNFi-naïve and TNFi-experienced patient groups.
Keywords:
